A member of our team will contact you soon to discuss sponsorship opportunities and more.
You will receive a confirmation email soon; please contact us if you have any questions.
The Sponsorship Program provides non-government funding to support the projects outlined in the TBI Precision Research Roadmap to accelerate progress and results.
Your sponsorship will help us drive a new era of research for TBI that advances a first generation of FDA-approved diagnostics and treatments.
Sponsorship levels are based on total annual or combined (3 year) commitment for individual or multiple programs, projects or infrastructure efforts delineated by the Precision TBI Research Roadmap. Commitments are formalized through a Grant or Gift Agreement with Cohen Veterans Bioscience, subject to Alliance terms & conditions, and payments are made annually in accordance with commitment terms.
Please contact us with any questions or to learn more about sponsorship.
| Sponsorship Level & Benefits |
Inaugural Sponsor‡ |
Platinum |
Gold |
Silver |
| Industry/Not-for-profit/Foundations/Individual Donors |
Gold or Platinum Level committed by March 31, 2023 |
$2-5M+ |
$500K-2M |
$100-500K |
| Seat on Inaugural Executive Committee (Y1) |
1‡ |
|||
| Weighted vote on Industry, Foundation or Partners Stakeholder Council |
After Y1, to level of sponsorship |
3 |
2 |
1 |
| Invitations to attend BTB Summit Annual Conferences |
4 |
4 |
2 |
1 |
| Branding opportunities |
Premium placement & recognition of support |
Premium placement & recognition of support |
Logo on Program Materials |
Logo on Program Materials |
| Membership Program benefits* |
Included |
Included |
Included |
Included |
Contribution levels are assessed based on organization type and worldwide annual revenue. Commitments are formalized through a Letter of Agreement with Cohen Veterans Bioscience and payments are made annually. The membership term is one year from execution date. Multi-year discounts (10%) will be applied for commitments of 3 or more years, paid up front.
Your annual membership donation may be tax deductible and will help us drive a new era of research for TBI that advances a first generation of FDA-approved diagnostics and treatments.
|
Not-for-Profit/Foundation Membership |
|
|
Organization Size (Revenue) |
Annual Membership Fee |
|
< $200K |
$500 |
|
$200K – 1 Million |
$1,000 |
|
$1 – 5 Million |
$2,500 |
|
$5 – 10 Million |
$5,000 |
|
$10 -20 Million |
$10,000 |
|
$20 – 50 Million |
$15,000 |
|
> $50 Million |
$20,000 |
|
Industry Membership |
|
|
Organization Size (Revenue) |
Annual Membership Fee |
|
< $1 Million |
$5,000 |
|
$1 – 10 Million |
$10,000 |
|
$10 – 50 Million |
$20,000 |
|
$50 – 100 Million |
$35,000 |
|
> $100 Million |
$50,000 |
Individual Membership (Free)
Membership to the TBI Action Alliance for individuals is free of charge.
Your membership benefits include:
To support the efforts of the TBI Action Alliance, and to help us drive a new era of research for TBI and advance a first generation of FDA-approved diagnostics and treatments, we ask that you consider making a tax-deductible donation in the amount of your choosing.
Please use the link below to make a one-time or recurring donation to support the TBI Action Alliance.
Trainee (students, post-doctoral) Membership ($50/year)
Your annual professional membership donation will help us drive a new era of research for TBI and advance a first generation of FDA-approved diagnostics and treatments.
Your membership benefits include:
Academic/Professional Membership ($500/year)
Your annual professional membership donation will help us drive a new era of research for TBI and advance a first generation of FDA-approved diagnostics and treatments.
Your membership benefits include:
The Challenge
Every year, millions of Americans, including Veterans, active military, first responders and public safety personnel, experience traumatic brain injuries and their associated devastating chronic effects, including suicide.
Yet, in 2023, we still have no FDA-approved TBI diagnostics or treatments.
The Facts
By presenting a unified and powerful voice to policymakers, funders, scientists and others who support TBI research efforts, we can ensure our priorities become theirs.
Build a TBI Precision Research Roadmap and support scientific, regulatory and government policies that place TBI research at the top of the national agenda and ensure adequate funding and resources to execute it.
Engaging the Community in the establishment of the Research Roadmap and holding its execution accountable to the Community as well.
The nexus of need, capital and aligned research priorities will attract new innovative thinkers and foster the advancement of new innovative approaches for TBI.
We will track progress against roadmap milestones and report out to the Alliance membership progress of collective efforts.
Cohen Veterans Bioscience (CVB), a national, nonpartisan 501c3 non-profit research organization dedicated to fast-tracking the development of diagnostic tests and personalized therapeutics for brain health, established the Brain Trauma Blueprint – a framework for generating and executing precision research roadmaps.
Through this framework, CVB has convened TBI Researchers and other stakeholders at State of the Science Summits to identify and publish consensus challenges and recommendations for TBI research.
The resulting TBI Precision Research Roadmap outlines the research projects & policies needed to accelerate a first generation of precision diagnostics and targeted treatments for TBI and also the systemic changes required to ensure that all those suffering from TBI can get access to these new innovations, and other support and care, they so desperately need.
The TBI Precision Research Roadmap focuses on 7 Lines of Effort:
We believe that a different model is needed to achieve success – a model where we collaborate to identify the most pressing research gaps and work collectively to address those gaps and ensure our work is not done in isolation, but as part of a more coordinated effort with the right resources and the right focus on each of the Roadmap Goals & Objectives.
We are at a crossroads of TBI Research. While there has been increased awareness and funding, we have not made enough progress.
The time is now to embark on a new model of research, where researchers, the government, industry and those with lived experiences come together to focus on achieving specific and measurable objectives that will transform the lives of people who suffer a TBI.
We ask that you join us in this critical fight for our Veterans and others who have suffered long enough and become a Member of the TBI Action Alliance.
Organizations that provide funding for TBI Action Alliance projects or activities
Individual Membership (Free)
Membership to the TBI Action Alliance for individuals is free of charge.
Your membership benefits include:
To support the efforts of the TBI Action Alliance, and to help us drive a new era of research for TBI and advance a first generation of FDA-approved diagnostics and treatments, we ask that you consider making a tax-deductible donation in the amount of your choosing.
Please use the link below to make a one-time or recurring donation to support the TBI Action Alliance.
Trainee (students, post-doctoral) Membership ($50/year)
Your annual professional membership donation will help us drive a new era of research for TBI and advance a first generation of FDA-approved diagnostics and treatments.
Your membership benefits include:
Academic/Professional Membership ($500/year)
Your annual professional membership donation will help us drive a new era of research for TBI and advance a first generation of FDA-approved diagnostics and treatments.
Your membership benefits include:
Contribution levels are assessed based on organization type and worldwide annual revenue. Commitments are formalized through a Letter of Agreement with Cohen Veterans Bioscience and payments are made annually. The membership term is one year from execution date. Multi-year discounts (10%) will be applied for commitments of 3 or more years, paid up front.
Your annual membership donation may be tax deductible and will help us drive a new era of research for TBI that advances a first generation of FDA-approved diagnostics and treatments.
1 Manley, G.T. and Maas, A.I. (2013) JAMA 310, 473-474.
2 Haarbauer-Krupa J, et al. (2021) Epidemiology of chronic effects of traumatic brain injury. Journal of neurotrauma. 2021 Dec 1;38(23):3235-47.
3 Helmick et al (2015) Brain Imaging and Behavior. Sep;9(3):358-66.
4 Iverson, Dardis & Pogoda (2017) Comprehensive Psychiatry, 74, 80–87. doi:10.1016/j.comppsych.2017.01.007
5 Valera et al. (2018) Journal of Neurotrauma, 36,661–668. doi:10.1089/neu.2018.5734
6 Gardner et al. (2015) Journal of Neurotrauma, 35:889–906. doi: 10.1089/neu.2017.5371
7 Dewan et al. (2016) World Neurosurgery, 91:497-509.e1 doi: 10.1016/j.wneu.2016.03.045
8 Frieden TR, Houry D, Baldwiin G. (2015) Report to Congress on Traumatic Brain Injury in the United States: Epidemiology and Rehabilitation. Atlanta, GA: CDC 2015. https://www.cdc.gov/traumaticbraininjury/pdf/tbi_report_to_congress_epi_and_rehab-a.pdf
Eligibility Overview
About the Study Sponsor
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
There are many different ways to find out about clinical research opportunities that might be of interest to you. Many doctors offices have brochures or advertisements about studies they are conducting or someone in their practice or hospital are conducting. A local study site might advertise on the radio or on the internet about their study. The sponsor of a study may have a website dedicated to informing people about the study. These websites may allow you to see if there is a study site near you.
Many patient advocacy groups also list available clinical studies on their websites. And finally, as all clinical studies of new treatments are required to be listed on a national registry, you can also search for your area of interest and “recruiting” or “not yet recruiting” at ClinicalTrials.gov.
Cohen Veterans Bioscience has several studies that are ongoing or about to start that you may be interested in learning more about.
The NNL is an ongoing study that is enrolling healthy volunteers to have a series of brain MRI scans taken in a single day to help build an understanding of what normal MRIs look like at different ages and in different sexes. This imaging reference library could be used to simply and objectively diagnose conditions like TBI and PTSD because having a library of normal brain scans can help define what is different in MRIs taken from people with PTSD or TBI.
The study is being conducted at three sites, the University of Virginia, the University of Utah, and Baylor College of Medicine.
40Winks is a CVB-sponsored study that is helping us build a platform for conducting trials virtually. Participants will be screened and enrolled through the study web portal and, if they qualify, will receive two wearable and home sensor devices in the mail to use for two weeks. During this time, we will research if this approach and method can be used to measure people’s health in their home environment, without having to travel to a study site.
40Winks will start enrolling in early 2023.
This study will evaluate whether sleep data from a wearable device can provide more accurate information about the patient’s sleep habits and patterns than the patient’s memory recall. It will also evaluate whether having this information improves the clinician-patient CBTi session for better treatment outcomes.
This study will begin in early 2023 and link to the enrollment site will be added at that time.
This study is for both health volunteers interested in clinical research and those with PTSD, mTBI or concussion, depression, or insomnia who are looking for the next opportunity to join a new treatment trial or want to contribute their data to gain a better understanding of their condition.
The registry will being asking for volunteers in mid-2023 and an active link for more information will be added here at that time.
Interested in joining on of our studies or getting more information? Feel free to reach out to us today.
Suicide rates among Veterans are not improving.
We can and must do better.
Tragically up to 22 American Veterans and service members die by suicide daily.
Nearly 300,000 Veterans who returned from the wars in Iraq and Afghanistan are suffering from PTSD.
Veterans and service members need more treatment options.
Despite decades of promising research and more than $1.1 billion spent on clinical trials1, no new drugs for PTSD and TBI have successfully advanced to FDA approval. And the research pipeline for new devices and therapies is thin as many pharmaceutical companies have abandoned research into PTSD and TBI.
Complex problems require a new approach that embraces collaborative science conducted to the highest standards of quality and with an openness to share data towards a common goal.
Co-founded by Cohen Veterans Bioscience, the Coalition to Heal Invisible Wounds brings together leading non-profit organizations seeking to advance a comprehensive research-focused advocacy agenda to address the invisible wounds of war—PTSD and TBI—as well as to address co-morbid conditions such as pain and substance use disorders, which are known to dramatically increase the risk of suicide among Veterans and service members.
The Coalition seeks to promote reforms, policies and meaningful research investments that will spur new research discoveries and advance a precision medicine approach for the invisible wounds of war.
Veterans and service members have earned the right to world-class health care, but doctors have too few treatment options. Congress should help researchers develop evidence-based therapies that are tested and proven by rigorous, randomized clinical trials.
The United States Department of Veterans Affairs (VA) and The United States Department of Defense (DoD) have outstanding assets and institutional strengths and can become leading partners in delivering new precision medicine approaches for PTS and TBI. Several collaborative initiatives have outlined gaps in the current knowledge and recommendations to move the research forward.
Congress should compel the VA and DoD to develop a cohesive research strategy for the invisible wounds that builds on public-private partnerships.
When available treatment options fail, many Veterans feel resigned to take their mental health care into their own hands and turn to alternative treatments with little clinical guidance.
Congress should direct the VA and DoD to demonstrate conclusively whether emerging treatments such as psychedelics, stellate ganglion block, and hyperbaric oxygen therapy work and in which people.
Bicameral and bipartisan ground breaking legislation, such as the Commander John Scott Hannon Mental Health Act, have been passed by every administration during the last 30 years, with little oversight into their implementation.
Congress should ensure full implementation of the Commander John Scott Hannon Mental Health Act, and especially on Sections 305, 306, 704, and 705, which created new tools for the VA to support leading-edge research.
The ultimate goal of the Coalition’s advocacy efforts is to realize better treatments, improved quality of life, new cures, and a reduction in the rate of suicide among Veterans and service members.
Chair
Co-Chair
For more information about the Coalition to Heal Invisible Wounds and how to become a member, please contact our Senior Director of External Affairs, Dr. Chantelle Ferland-Beckham.
Dr. Chantelle Ferland-Beckham, Ph.D.
Senior Director, External Affairs
Contact via Email
Fostering a collaborative approach to advancing solutions for brain trauma
Galvanizing the brain health ecosystem
The Brain Health Nexus initiative aims to unleash science and technology to build a new paradigm of collaboration to optimize brain health and prevent brain disease. In the current research landscape, each brain disease is addressed separately. But these diseases do not exist in isolation. We need coordinated action to broaden the focus from treating diseases at crisis points to prevention and wellness across the lifespan. It will take one interconnected community to break down barriers and borders, share data and insights, and bridge capital and opportunity.
Identifying biomarkers for brain disorders
The BRAINCommons provides secure access to a collaborative community and state-of-the-art analytic tools that facilitate high quality brain research.
By including data across neurodegenerative diseases, BRAINCommons facilitates research collaboration, data exploration, and reproducibility. The insights it creates will accelerate the development of new therapies for Parkinson’s and similar diseases.
– Todd Sherer, PhD
CEO, The Michael J. Fox Foundation for Parkinson’s Research
CVB’s digital health platform EarlySignal (EaSi) aims to improve the well-being of patients by improving how information is collected from wearables and other sensors. Quantifying health and disease with real-time data from wearable devices can enable clinicians to monitor patients’ health, diagnose patients more accurately and tailor treatments accordingly.
Our flagship biomarker discovery platform is a public-private partnership leveraging existing data and stored biosamples to identify biomarkers with the potential to diagnose PTSD and TBI, predict the progression of the conditions, and measure the efficacy of treatments. RAPID-Dx also designs studies to validate biomarkers for use in diagnostic and therapeutic development.
A biomarker is an objectively measured characteristic that may indicate a normal or pathologic disease process, or a response to a therapeutic intervention. By discovering and validating biomarkers, we can fast-track precision diagnostics and tailored therapeutics for brain disorders.
By joining RAPID-Dx, we are affirming our commitment to a new type of radically collaborative science defined by data sharing and coordination of efforts toward our shared goal of finding clinically-useful diagnostics and treatments for these invisible wounds of war. There is no doubt in my mind that coordinated team science will accelerate progress toward diagnosis and treatments. We are thrilled to be working with Cohen Veterans Bioscience.
– Rachel Ramoni, DMD, ScD
Chief Research and Development Officer at the Veterans Health Administration
Accelerating Drug Discovery Through Rigorous Preclinical Research
Our Preclinical Modeling platform creates alignment across the preclinical research community, offers scientific expertise and program management, and fills funding gaps to support impactful research.
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
©2023 Cohen Veterans Bioscience Privacy Policy | Terms of Use
